• About
    • Overview
    • Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Technology
    • LYTAC Platform
    • Publications
  • Pipeline
    • Programs
    • Disease Area Focus
  • Careers
    • Culture
    • Benefits
    • Job Openings
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financials
      • SEC Filings
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Contact

Technology

  • About
    • Overview
    • Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Technology
    • LYTAC Platform
    • Publications
  • Pipeline
    • Programs
    • Disease Area Focus
  • Careers
    • Culture
    • Benefits
    • Job Openings
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financials
      • SEC Filings
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Contact

Scientific Publications

Poster | November 05, 2026

LCA-0321 is a novel targeted protein degrader designed to specifically and rapidly eliminate TSHR autoantibodies for the treatment of Graves’ disease

American Thyroid Association Annual Meeting 2026

Read More

Article | In Revision

Selective degradation of pathogenic autoantibodies by lysosomal targeting chimeras for the treatment of myasthenia gravis

Read More

Poster | June 26, 2025

Catalytic Degradation of Circulating Targets by FcRn-mediated Cycling LYTACs

Keystone Symposium on Autophagosomes and Endolysosomes 2025

Read More

Article | In Revision

Catalytic degradation of circulating targets with FcRn-mediated cycling LYTACs

Read More

Article | In Revision

Monitoring lysosomal catabolism: a sensitive probe for assessing targeted lysosomal degradation of extracellular proteins

Read More

Article | March 25, 2021

LYTACs that engage the asialoglycoprotein receptor for targeted protein degradation

Nature Chemical Biology

Read More

Article | July 29, 2020

Lysosome-targeting chimaeras for degradation of extracellular proteins

Nature

Read More

lycia logo

400 East Jamie Court, Suite 200
South San Francisco, CA 94080

info@lyciatx.com
  • About
  • Technology
  • Pipeline
  • Careers
  • Investors
  • Contact

© 2026 Lycia Therapeutics | Privacy Policy | Terms of Use | Consumer Health Data Privacy Notice

logo
  • About
    • Overview
    • Team
    • Management
    • Board of Directors
    • Scientific Advisory Board
    • Partnering
  • Technology
    • LYTAC Platform
    • Publications
  • Pipeline
    • Programs
    • Disease Area Focus
  • Careers
    • Culture
    • Benefits
    • Job Openings
  • Investors
    • Overview
    • News & Events
      • Press Releases
      • Events & Presentations
    • Stock
      • Stock Quote & Chart
    • Governance
      • Documents & Charters
      • Board of Directors
      • Management Team
      • Committee Composition
    • Financials
      • SEC Filings
    • Shareholder Services
      • Investor FAQs
      • Email Alerts
      • Contact Us
  • Contact